Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Most non-small cell lung cancer (NSCLC) patients are diagnosed with advanced disease, making chemotherapy the primary treatment.
• Platinum-based chemotherapy, while effective, often leads to acquired or intrinsic chemo-resistance in NSCLC.
• The precise mechanisms underlying chemotherapy resistance in NSCLC remain incompletely understood.

Purpose of the Study:

• To investigate the role of inflammatory mediators in cisplatin resistance in non-small cell lung cancer (NSCLC).
• To explore the potential of targeting NF-κB as a therapeutic strategy for overcoming cisplatin resistance in NSCLC.

Main Methods:

• Utilized an isogenic model of cisplatin-resistant NSCLC (CisR) and its parental counterpart (PT).
• Assessed inflammatory mediator NF-κB and associated pathways using mass spectrometry, western blot, and qRT-PCR.
• Evaluated the efficacy of an NF-κB inhibitor (DHMEQ) in resensitizing CisR cells to cisplatin via viability assays and western blot analysis.

Main Results:

• Proteomic analysis revealed dysregulated NF-κB targets in CisR cells compared to PT cells.
• Increased NF-κB expression was observed in four out of five NSCLC sub-types examined (CisR vs. PT).
• DHMEQ treatment reduced NF-κB expression and resensitized CisR cells to cisplatin's cytotoxic effects.

Conclusions:

• Identified NF-κB as a significant therapeutic target in cisplatin-resistant NSCLC.
• Demonstrated that inhibiting NF-κB with DHMEQ can resensitize chemo-resistant NSCLC cells to cisplatin.